These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19432937)

  • 1. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis.
    Kontou-Fili K; Filis CI
    Allergy; 2009 Sep; 64(9):1384-5. PubMed ID: 19432937
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.
    da Silva EN; Randall KL
    J Allergy Clin Immunol Pract; 2013; 1(6):687-8. PubMed ID: 24565720
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.
    Galera C; Soohun N; Zankar N; Caimmi S; Gallen C; Demoly P
    J Investig Allergol Clin Immunol; 2009; 19(3):225-9. PubMed ID: 19610266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy.
    Soriano Gomis V; Gonzalez Delgado P; Niveiro Hernandez E
    J Investig Allergol Clin Immunol; 2008; 18(3):225-6. PubMed ID: 18564638
    [No Abstract]   [Full Text] [Related]  

  • 5. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.
    Kontou-Fili K
    Allergy; 2008 Mar; 63(3):376-8. PubMed ID: 18269681
    [No Abstract]   [Full Text] [Related]  

  • 6. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE.
    Kontou-Fili K; Filis CI; Voulgari C; Panayiotidis PG
    Ann Allergy Asthma Immunol; 2010 Jun; 104(6):537-9. PubMed ID: 20568389
    [No Abstract]   [Full Text] [Related]  

  • 7. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy.
    Bonadonna P; Zanotti R; Caruso B; Castellani L; Perbellini O; Colarossi S; Chilosi M; Dama A; Schiappoli M; Pizzolo G; Senna G; Passalacqua G
    J Allergy Clin Immunol; 2008 Jan; 121(1):256-7. PubMed ID: 18206512
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic reactions during maintenance immunotherapy with honey bee venom.
    Bousquet J; Ménardo JL; Velasquez G; Michel FB
    Ann Allergy; 1988 Jul; 61(1):63-8. PubMed ID: 3389573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The problem of anaphylaxis and mastocytosis.
    Müller UR; Haeberli G
    Curr Allergy Asthma Rep; 2009 Jan; 9(1):64-70. PubMed ID: 19063827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.
    Schulze J; Rose M; Zielen S
    Allergy; 2007 Aug; 62(8):963-4. PubMed ID: 17484729
    [No Abstract]   [Full Text] [Related]  

  • 12. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy.
    Niedoszytko M; de Monchy J; van Doormaal JJ; Jassem E; Oude Elberink JN
    Allergy; 2009 Sep; 64(9):1237-45. PubMed ID: 19627278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.
    Limb SL; Starke PR; Lee CE; Chowdhury BA
    J Allergy Clin Immunol; 2007 Dec; 120(6):1378-81. PubMed ID: 17936893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
    Sokol KC; Ghazi A; Kelly BC; Grant JA
    J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of passive antibody in bee venom anaphylaxis.
    Lessof MH; Sobotka AK; Lichtenstein LM
    Johns Hopkins Med J; 1978 Jan; 142(1):1-7. PubMed ID: 75280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
    Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
    Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
    González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
    J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyper-accelerated immunotherapy with Hymenoptera venoms].
    Sabbah A; Bonneau JC; Drouet M; Le Sellin J
    Allerg Immunol (Paris); 1987 Apr; 19(4):156-8, 160, 162-3. PubMed ID: 3453132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
    Douglass JA; Carroll K; Voskamp A; Bourke P; Wei A; O'Hehir RE
    Allergy; 2010 Jul; 65(7):926-7. PubMed ID: 19889117
    [No Abstract]   [Full Text] [Related]  

  • 20. [The key role of IgG4 subclass antibodies in the development of protection against allergic reactions to insect stings].
    Urbanek R; Dold S
    Monatsschr Kinderheilkd; 1986 Aug; 134(8):536-40. PubMed ID: 3773921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.